Studies in vitro on infectivity and sensitivity to antileishmanial drugs in New World Leishmania species transfected with the green fluorescent protein (pIR3(-)- eGFP)

Current chemotherapeutic agents for leishmaniasis have several disadvantages interfering with the effective treatment and therefore more and better antileishmanial drugs are needed. Discovery of candidates for leishmaniasis treatment requires not only accurate and precise methodologies but also well...

Full description

Autores:
Parodi Quintero, Adriana Julieth
Palacios Cortés, Génesis
Upegui Zapata, Yulieth Alexandra
Montoya Cuervo, Edwin Andrés
Vélez Bernal, Iván Darío
Robledo Restrepo, Sara María
Pulido Muñoz, Sergio Andrés
Tipo de recurso:
Article of investigation
Fecha de publicación:
2017
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/47251
Acceso en línea:
https://hdl.handle.net/10495/47251
Palabra clave:
Antiprotozoal Agents
Antiprotozoarios
Green Fluorescent Proteins
Proteínas Fluorescentes Verdes
Leishmaniasis
Parasitic Sensitivity Tests
Pruebas de Sensibilidad Parasitaria
Species Specificity
Especificidad de la Especie
Transfection
Transfección
https://id.nlm.nih.gov/mesh/D000981
https://id.nlm.nih.gov/mesh/D049452
https://id.nlm.nih.gov/mesh/D007891
https://id.nlm.nih.gov/mesh/D007896
https://id.nlm.nih.gov/mesh/D021261
https://id.nlm.nih.gov/mesh/D013045
https://id.nlm.nih.gov/mesh/D014162
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
Rights
openAccess
License
http://creativecommons.org/licenses/by/4.0/
Description
Summary:Current chemotherapeutic agents for leishmaniasis have several disadvantages interfering with the effective treatment and therefore more and better antileishmanial drugs are needed. Discovery of candidates for leishmaniasis treatment requires not only accurate and precise methodologies but also well-known biological system to measure infectivity of parasites and antileishmanial activity of the new compounds. Significant variation in the in vitro and in vivo infectivity and sensitivity to established and experimental drugs in Leishmania strains are reported. This work reports the in vitro biological behavior and antileishmanial drugs sensitivity of different green fluorescent protein transfectant Leishmanias strains. The in vitro growth kinetic and infectivity to U937 cells vary slightly in the Leishmania transfectant strains in comparison with their correspondant wild-type. However, the insertion of the pIR3(-)-eGFP may affect the sensitivity of the parasites to meglumine antimoniate (MA) and miltefosine but not to amphotericin B (AMB) and pentamidine isethionate. In consequence, AMB or pentamidine isethionate but not MA or miltefosine should be used as antileishmanial control drugs during in vitro assays of antileishmanial activity. Furthermore, is recommended to test compounds against more than one Leishmania strain in order to verify that the antileihmanial activity of these compound is similar among species.